| Document |
Document Title |
|
WO/2016/016178A1 |
The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).
|
|
WO/2016/017537A1 |
Provided is an α-aminoalkylphenone compound that has excellent stability and low sublimability, that efficiently generates radicals in response to a bright line of 365 nm (an i-line) or the like, and that is useful as a polymerization i...
|
|
WO/2016/016370A1 |
The invention pertains to novel FLT3receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.
|
|
WO/2016/013633A1 |
A compound represented by formula (I) or a salt thereof has an excellent noxious organism control activity, particularly an excellent miticidal activity and/or an excellent insecticidal activity, is highly safe, and can be synthesized in...
|
|
WO/2016/011231A1 |
Compositions and methods using silicon-based cross-coupling agents in the formation of carbon-carbon and carbon-nitrogen bonds are described.
|
|
WO/2016/009871A1 |
Provided is a photosensitive composition that uses, as a photopolymerization initiator, a compound that is useful as a highly sensitive photopolymerization initiator that is activated by efficiently absorbing near-ultraviolet light of 36...
|
|
WO/2015/177763A9 |
The present invention relates to electro-active, both achiral and chiral, polyconjugated macrocyclic oligoarene and oligoheteroarene compounds, optionally used as single enantiomers, and derivatives thereof, which are used in the manufac...
|
|
WO/2016/010538A1 |
Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the com...
|
|
WO/2016/005318A1 |
The present invention provides novel amino lipids and a method for synthesizing these compounds. According to the invention, the amino lipids have a structure of the following formula (I) wherein Z is either hydrogen or -X1 R1, R1 and R2...
|
|
WO/2016/001390A1 |
The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof Formula (I), and its uses to treat a disorder associated with protein misfolding stress and in particular with an...
|
|
WO/2016/004202A1 |
The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of Formula (I) or (II)) and methods of preparing the lipidoids. A described lipidoid includes R-C(=0)-0- moieties (where R is a lipid moiety), which ...
|
|
WO/2015/200619A1 |
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition ...
|
|
WO/2015/199952A1 |
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defin...
|
|
WO/2015/200674A1 |
The invention described herein relates generally to neuroactive compounds and compositions for the treatment psychotic disorders, methods for treating psychosis using these neuroactive compounds, and methods for screening for novel neuro...
|
|
WO/2015/195776A1 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivaties that possess unique antiviral activity are provided as HIV maturation inhibi...
|
|
WO/2015/189554A1 |
The present invention provides apalladium(II)complex of formula (1) or a palladium(II) complex of formula (2). R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R18, R19, R20, R21, R22, R23 and R24, m, E and X are described in the speci...
|
|
WO/2015/189050A1 |
A method for synthesis of N-methyl piperazine diphenolamide is presented. The method includes contacting diphenolic acid with N-methyl piperazine to form a reaction mixture; and heating the reaction mixture to form a reaction product inc...
|
|
WO/2015/114395A9 |
The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an e...
|
|
WO/2015/180342A1 |
The present invention provides a deuterium substituted 1-[2-(2,4-dimethyl-thiophenyl)-phenyl] piperazine compound with a structure represented by formula (I) or a derivative thereof, a pharmaceutical composition containing the compound o...
|
|
WO/2015/180552A1 |
Disclosed is a method for preparing Volasertib (I), comprising the following steps: an intermediate 2-amino-7-ethyl-7,8-dihydro-5-methyl-8-isopropyl-(7R)-6(5H)-
pteridinone (II) is nucleophilically substituted with an intermediate N-[tra...
|
|
WO/2015/181186A1 |
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions con...
|
|
WO/2015/180693A1 |
Disclosed are a compound of general formula I, or a stereoisomer, an enantisomer, a diastereoisomer thereof or their mixture, or pharmaceutically acceptable salts and solvates thereof: I, wherein an A ring indicates an optionally substit...
|
|
WO/2015/178039A1 |
Provided is a rubber composition which can suppress coloration of the surface of a rubber article by having better weather resistance than conventional rubber compositions. This rubber composition is characterized by being formed by mixi...
|
|
WO/2015/177325A1 |
Compounds of the formula la or lb: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, D, E, G, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of making the ...
|
|
WO/2015/174402A1 |
The present invention improves curability and reduces post-curing migration in a photopolymerization initiator. As a photopolymerization initiator, the present invention uses a compound obtained as a result of a Michael addition reaction...
|
|
WO/2015/173392A1 |
The present invention relates to novel substituted oxindole derivativesof formula I, wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compound...
|
|
WO/2015/173393A1 |
The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substitue...
|
|
WO/2015/169130A1 |
Provided in the present invention are a new intermediate II and a synthesis process thereof, the synthesis process comprising: (a) using a compound of formula I as a raw material, the intermediate II is obtained by diazo reaction, follow...
|
|
WO/2015/162610A1 |
The present invention is directed to phenyl substituted cyclohexenyl compounds of formula (I), compositions comprising them and uses thereof for the preparation of medicaments for the treatment of obesity and any disease or disorder asso...
|
|
WO/2015/162622A1 |
The present invention discloses an in-situ process for preparation of Linezolid polymorphic Form II free of impurities.
|
|
WO/2015/159225A1 |
An organometallic complex of a tridentate bis(phosphine)-carbodicarbene ligand and a transition metal, is described. In some embodiments the ligand has the structure of Formula (I): The complexes are useful in methods of making an allyli...
|
|
WO/2015/158908A1 |
The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).
|
|
WO/2015/158313A1 |
Provided herein are sulfonamide derivatives or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer...
|
|
WO/2015/155153A1 |
The present invention provides a new synthetic process for the production of 1 -(2-((2,4-dimethylphenyl)thio)phenyl)piperazine (vortioxetine), a drug for the treatment of depression and anxiety, which is conducted via (2,4-dimethylphenyl...
|
|
WO/2015/154191A1 |
Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ...
|
|
WO/2015/150390A1 |
The present invention relates to compounds of formula (I) wherein X is N or P; -SO3- is -O-S(O)2 -or -S(O)2-O-; and n and R1 to R5 are defined below, and to their use as additives for electrolyte compositions, in particular in electrolyt...
|
|
WO/2015/149502A1 |
A method for preparing a bis(fluorosulfonyl)imide onium salt, which comprises a step of reacting the bis(chlorosulfonyl)imide shown by structural formula (A), the onium ion halide shown by structural formula (B) and hydrogen fluoride to ...
|
|
WO/2015/143154A1 |
The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.
|
|
WO/2015/143162A1 |
The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.
|
|
WO/2015/127549A1 |
The invention relates to compounds useful in treating conditions associated with voltage- gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic...
|
|
WO2015120821A1 |
Disclosed are water-soluble propofol derivatives, preparation method thereof, anaesthesia method using same, use thereof as prodrugs and use thereof for preparing vein dope medicines. The water-soluble propofol derivatives have a general...
|
|
WO/2015/120820A1 |
The present invention discloses a class of carboxylic acid derivatives and use thereof in preparation of prodrugs. The carboxylic acid derivatives have the general formula (I): R1 being H or an alkyl; X being H or F; Y being F or a fluor...
|
|
WO/2015/119111A1 |
The problem addressed by the present invention is to provide an anti-prion compound having high crystallinity and high crystal stability, and to provide an agent for the prevention, amelioration, and treatment of prion disease. The prese...
|
|
WO/2015/116786A1 |
In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another asp...
|
|
WO/2015/110883A1 |
The present invention provides an improved process for preparation of the substantially pure trazodone and its hydrochloride salt. The process comprises reaction of the compound- Π (as described) with the compound-Ill (as described) opt...
|
|
WO/2015/107057A1 |
The present invention provides a new synthetic process for the production of 1-(2-((2,4- dimethylphenyl)thio)phenyl)piperazine (vortioxetine), a drug for the treatment of depression and anxiety, which is conducted via (2-(piperazine-1-yl...
|
|
WO/2015/108038A1 |
The present invention addresses the problem of providing: a compound which is useful for the prevention or treatment of hyperphosphatemia or a hyperphosphatemia-related disease, or a pharmacologically acceptable salt of the compound; and...
|
|
WO/2015/109130A1 |
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
|
|
WO/2015/096883A1 |
This invention relates to N-alkyl-N'-poly(oxyalkyl)hexapyrimidine- betaines of the formulae (la) - (Ic) and mixtures thereof, formulae (la) - (Ic) in which R1 is C8-C30-alkyl or C8-C30-alkenyl, R2 is hydrogen, C1-C3-alkyl, -COOH or a gro...
|
|
WO/2015/097475A1 |
The present invention relates to compounds of formula (I) shown below: wherein Q is as defined herein. The compounds of formula (I) act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The pr...
|
